Abbott’s Volt PFA System Debuts in Canada
Abbott announced the first Canadian use of its Volt Pulsed Field Ablation (PFA) System at McGill University Health Centre in Montreal to treat patients with atrial fibrillation. Health Canada authorized the system in April 2026 based on the VOLT-AF IDE study of 392 patients across 40 centers, which demonstrated safety and effectiveness in patients with paroxysmal and persistent AFib. The next-generation system features a balloon-in-basket catheter designed for improved tissue contact and targeted energy delivery, with fewer catheter exchanges and reduced radiation exposure. Integrated with Abbott’s EnSite X EP System, Volt also supports 3D cardiac mapping and the use of conscious sedation as an alternative to general anesthesia, potentially improving procedural efficiency and recovery.
Knight Advances Gemtesa Toward Canadian Review for Overactive Bladder
Knight Therapeutics announced that Health Canada has accepted its New Drug Submission for Gemtesa (vibegron), advancing the therapy toward potential approval in Canada for adults with overactive bladder. The submission covers OAB with urge urinary incontinence, urgency, and urinary frequency, as well as OAB with nocturia in adult males receiving pharmacological therapy for benign prostatic hyperplasia. Gemtesa is a selective β3-adrenergic receptor agonist, and the acceptance begins Health Canada’s regulatory review without indicating approval. Knight is developing the therapy in partnership with Sumitomo Pharma America under an exclusive Canadian supply and distribution agreement.
Optimi Plans Phase 3 Trial of MDMA-Assisted Therapy for PTSD in Canada
Optimi Health plans to initiate a Health Canada-authorized Phase 3 clinical trial in 2027 evaluating synthetic MDMA-assisted therapy for PTSD, following a planned Phase 2 psilocybin trial for major depressive disorder. The study is expected to enroll up to 100 participants across multiple Canadian sites, focusing on veterans and current or former frontline workers, including military, police, paramedics, firefighters, and healthcare workers. Participants will receive synthetic MDMA HCl during two supervised sessions alongside psychotherapy, with PTSD severity assessed using the clinician-administered CAPS-5 scale. MDMA-assisted therapy remains investigational in Canada, with Optimi’s products yet to receive Health Canada market authorization.
Sanofi Inaugurates $925M (CAD) Flu Vaccine Manufacturing Facility in Canada
Sanofi inaugurated the Charles Best Building in Toronto, a CAD $925 million flu vaccine manufacturing facility adding end-to-end vaccine production capacity in Canada and strengthening preparedness for future influenza pandemics. The investment includes C$415 million from the Government of Canada and C$55 million from Ontario and is expected to create approximately 300 skilled jobs. The facility will manufacture Fluzone High-Dose, an influenza vaccine indicated for adults aged 65 and older that contains four times the antigen of standard-dose vaccines. Fully operational and pending regulatory approval, the facility is expected to begin production in early 2027 for the 2027–28 flu season, expanding Canada’s domestic vaccine manufacturing capabilities.
